Health and Medical News and Resources

General interest items edited by Janice Flahiff

[Reblog] Investigating the Safety of the Probiotic Lactobacillus reuteri in Infants With Colic

From the US National Institutes of Health (NIH), specifically

National Center for Complementary and Integrative Health (NCCIH)

NIH…Turning Discovery Into Health
[This page last modified January 24, 2018]
Baby Crying

Findings from a recent preliminary trial, published in The Journal of Pediatrics, suggest that the probiotic Lactobacillus reuteri strain DSM 17938 may be safe for use in infants with colic. These results, however, must be interpreted with caution because of the small study size. The study, funded in part by NCCIH, was led by researchers from the University of Texas Health Science Center at Houston and Louisiana State University Health Sciences Center.

Colic is a condition that results in inexplicable and severe crying in otherwise healthy newborns. The causes of this condition are unknown, but researchers suspect the gut is involved because symptoms usually worsen after feedings. An emerging body of evidence suggests that colicky infants may have an abnormal microbiome (community of microorganisms) in the gut, which may lead to inflammation, causing discomfort.      

In this study, 21 infants were randomly assigned into two groups in a 2:1 ratio: a probiotic group and a placebo group. A total of 16 infants completed the study. The infants received a daily dose of either L. reuteri strain DSM 17938 or placebo (sunflower oil) for 42 days. The goals of the study were to determine the safety of administering L. reuteri strain DSM 17938 to infants while also exploring its effects on crying, inflammation, and other biomarkers that may be useful in future studies; the study was not designed to assess the probiotic’s efficacy.

During the trial, no severe adverse events were observed, nor were there any major differences between the two groups in blood indicators of safety. Thus, the study suggests that L. reuteri strain DSM 17938 may be safe for infants with colic. The researchers did not observe a significant difference in colic symptoms between the two groups but did identify findings that may suggest gut inflammation. At the beginning of the study, blood from over 50 percent of the colicky infants contained low concentrations of neutrophils, a type of white blood (immune) cell. This is consistent with an infection or inflammation. Interestingly, the blood level of neutrophils increased in the probiotic-treated but not the placebo-treated infants, an observation that warrants future investigation.

Reference

Publication Date:
September 29, 2017

January 26, 2018 Posted by | Consumer Health, Health News Items, Uncategorized | , , | Leave a comment

Beneficial Bacteria May Help Ward Off Infection

 

English: Template for Template:Food safety

English: Template for Template:Food safety (Photo credit: Wikipedia)

 

From the 19 July 2012 article at Science News Daily

 

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

In a new study, Cheryl Nickerson and her group at ASU’s Biodesign Institute, in collaboration with an international team including Tom Van de Wiele and lead author Rosemarie De Weirdt at Ghent University, Belgium, explore the role of Lactobaccilus reuteri — a natural resident of the human gut — to protect against foodborne infection.

Their results demonstrate that this beneficial or probiotic organism, which produces an antimicrobial substance known as reuterin, may protect intestinal epithelial cells from infection by the foodborne bacterial pathogen Salmonella….

Bacterial Blizzard

A swarm of some hundred trillion bacteria occupies the human body, outnumbering human cells by about 10 to 1. Among these are members of the genus Lactobacilli, some of which have been associated with therapeutic, probiotic properties, including anti-inflammatory and anti-cancer activity.

The current study zeros in on Lactobacillus reuteri — one of the more than 180 species of Lactobacilli. The group investigated the potential of this bacterium to inhibit the early stages ofSalmonella infection, seeking to identify plausible mechanisms for such inhibitory effects.

Intestinal infections by non-typhoidal Salmonella strains induce diarrhea and gastroenteritis, and remain a leading source of foodborne illness worldwide. Such infections are acutely unpleasant but self-limiting in healthy individuals. For those with compromised immunity however, they can be deadly and the alarming incidence of multi-drug resistant Salmonellastrains has underlined the necessity of more effective therapeutics.

The use of benign microorganisms offers a promising new approach to treating infection from pathogens like Salmonellaand indeed, L. reuteri has been shown to help protect against gastrointestinal infection and reduce diarrhea in children.

Safeguarding cells

The origin of L. reuteri’s protective role still remains unclear, and the present study investigated whether reuterin, a metabolite produced by L. reuteri during the process of reducing glycerol in the gut, could be one of the keys to protection. While it has been speculated that reuterin acts by regulating immune responses or competing with Salmonella for key binding sites, the current study represents the first in vitro examination of host-pathogen interactions using human intestinal epithelium in the presence of reuterin-producing L. reuteri.

 

 

July 23, 2012 Posted by | Medical and Health Research News | , , , , , , , , | Leave a comment

   

%d bloggers like this: